PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
16.39%
Revenue growth at 50-75% of CRON.TO's 28.47%. Martin Whitman would worry about competitiveness or product relevance.
6.16%
Gross profit growth at 50-75% of CRON.TO's 11.04%. Martin Whitman would question if cost structure or brand is lagging.
-39.85%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-39.85%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
2.92%
Net income growth under 50% of CRON.TO's 121.13%. Michael Burry would suspect the firm is falling well behind a key competitor.
-2.20%
Negative EPS growth while CRON.TO is at 119.61%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2.20%
Negative diluted EPS growth while CRON.TO is at 115.69%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
29.60%
Share count expansion well above CRON.TO's 5.90%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
23.80%
Diluted share count expanding well above CRON.TO's 33.96%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-62.19%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
32.43%
Positive FCF growth while CRON.TO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-90.89%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-90.89%
Negative 5Y OCF/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
336.85%
Positive 3Y OCF/share CAGR while CRON.TO is negative. John Neff might see a big short-term edge in operational efficiency.
228.97%
10Y net income/share CAGR of 228.97% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
228.97%
Net income/share CAGR of 228.97% while CRON.TO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
879.72%
3Y net income/share CAGR above 1.5x CRON.TO's 223.83%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
539.94%
Equity/share CAGR of 539.94% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
539.94%
Equity/share CAGR of 539.94% while CRON.TO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
1391.78%
3Y equity/share CAGR at 75-90% of CRON.TO's 1659.22%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.51%
AR growth well above CRON.TO's 22.62%. Michael Burry fears inflated revenue or higher default risk in the near future.
2.64%
Inventory shrinking or stable vs. CRON.TO's 12.71%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
63.87%
Positive asset growth while CRON.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
33.53%
Positive BV/share change while CRON.TO is negative. John Neff sees a clear edge over a competitor losing equity.
-4.80%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-65.35%
Our R&D shrinks while CRON.TO invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
26.25%
SG&A declining or stable vs. CRON.TO's 56.42%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.